FDA Authorizes KMT2A FISH Test as Companion Diagnostic for Acute Leukemia Therapy
The breakapart probe detects gene rearrangements in acute leukemia patients to identify candidates for menin inhibitor therapy.
The breakapart probe detects gene rearrangements in acute leukemia patients to identify candidates for menin inhibitor therapy.
A novel assay that identifies a unique molecular marker in acute myeloid leukemia patients may revolutionize how the disease is detected.
Identifying recurrent genetic alterations in myeloid neoplasms has improved diagnosis and expanded targeted treatments available to patients.
To better treat patients with acute myeloid leukemia, researchers discovered a novel subtype of the cancer via proteome and genetic analysis.
Read MoreResearchers have developed a new protocol for monitoring acute lymphoblastic leukemia to inform more effective treatment strategies.
Read MoreBioFluidica, a privately held biotechnology company, plans to commercialize its LiquidScan Automated Liquid Biopsy System.Â
Read MoreThe grant will allow Qlucore to expand Qlucore Diagnostics software with a focus on RNA-profiling of glioma and acute leukemia.
Read MorePixCell’s HemoScreen may be used to monitor pathological blood samples, improving treatment process for hematological patients.
Read MoreThe blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read MoreA noninvasive blood test may provide a ‘crystal ball’ for early detection of infections, leading to increased cure rates among pediatric leukemia patients.
Read MoreThe Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read MoreThe latest update is beneficial to researchers investigating myeloid disorders, and is now enabled with BCR-ABL fusion gene and KMT2A-PTD detection.
Read MoreBluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read MoreThe panel has been tested to show excellent concordance with array data, and can detect both small and large CNVs, indels, LOH, and SNVs.
Read MoreSight Diagnostics’ patented Olo analyzer digitizes blood into images to perform the most common blood test in minutes, using just two drops of blood.
Read MoreThe Karius test detected bloodstream infections in 75% of cases as early as 3 days before pediatric leukemia patients became symptomatic.
Read MoreAI-driven digital pathology can accelerate cancer diagnosis and clinical trial recruitment.
Read MoreStrong concordance with standard-of-care methods shows how the Saphyr mapping system can transform cytogenetic workflows and improve blood cancer treatment.
Read More